ASMB beat EPS expectations by 28.31%
May 15, 2025, 10:34 PM
0.00%
What does ASMB do
Assembly Biosciences, a biotechnology company based in South San Francisco, develops treatments for chronic hepatitis B and other infectious diseases, with a pipeline including multiple antiviral agents. The company, which went public in December 2010, employs 65 people.
Assembly Biosciences (ASMB) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Assembly Biosciences's actual EPS was -$1.17, beating the estimate of -$1.63 per share, resulting in a 28.31% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.